Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Taurursodiol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amylyx to Discontinue ORION AMX0035 Program in Palsy (PSP)
    Amylyx to Discontinue ORION AMX0035 Program in Palsy (PSP)

    27 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250827304923/en/Amylyx-Pharmaceuticals-to-Discontinue-ORION-Program-of-AMX0035-for-Progressive-Supranuclear-Palsy-PSP

    BUSINESSWIRE
    27 Aug 2025
    Share Share
    Amylyx Reports Positive Long-Term HELIOS Trial Data
    Amylyx Reports Positive Long-Term HELIOS Trial Data

    12 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250512643540/en/Amylyx-Pharmaceuticals-Announces-Positive-Long-Term-Results-from-Phase-2-HELIOS-Clinical-Trial-of-AMX0035-in-People-with-Wolfram-Syndrome

    BUSINESSWIRE
    12 May 2025
    Share Share
    Amylyx Publishes AMX0035 Data On Alzheimer's Biomarkers
    Amylyx Publishes AMX0035 Data On Alzheimer's Biomarkers

    12 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240812995807/en

    BUSINESSWIRE
    12 Aug 2024
    Share Share
    Amylyx stock slips 6% after phase 2 rare disease data drop
    Amylyx stock slips 6% after phase 2 rare disease data drop

    11 Apr 2024

    // Gabrielle Masson FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/nearly-week-after-pulling-relyvrio-amylyx-engage-regulators-about-path-another-rare-disease

    Gabrielle Masson FIERCE BIOTECH
    11 Apr 2024
    Share Share
    Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers
    Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers

    05 Apr 2024

    // PRESS RELEASE

    https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-formal-intention-to-remove-relyvrior/albriozatm-from-the-market-provides-updates-on-access-to-therapy-pipeline-corporate-restructuring-and-strategy

    PRESS RELEASE
    05 Apr 2024
    Share Share
    Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
    Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

    09 Mar 2024

    // PRESS RELEASE

    https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-topline-results-from-global-phase-3-phoenix-trial-of-amx0035-in-als

    PRESS RELEASE
    09 Mar 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.